#RadioMetal
May 19, 2025 at 2:37 PM
Seen in the Paris metro.
"Over 5 million of you have listened to Gojira on Spotify since the summer".
Gold medal for spin when you see how Metal is treated in the mainstream media and on streaming platforms.
But it's still excellent news !
Photograph by RadioMetal 🙏 (a great media).
December 11, 2024 at 9:03 AM
Some old nsfw I made of Odile having some fun with Alastor’s tentacles~

#RadioMetal #RadioMetalNSFW #OdiAl #OdiAlNSFW #HHOC #nsfwoc #tentaclekink
May 17, 2025 at 5:35 PM
Global DOTA Chelator GMP Grade Radiometal Coordination Therapy Market to Reach USD 512 Million by 2034, Growing at 8.4% CAGR
www.24chemicalresearch.com/reports/3092...
DOTA Chelator GMP Grade Radiometal Coordination Therapy Market, Outlook and Forecast 2026-2034
DOTA Chelator GMP Grade Radiometal Coordination Therapy Global DOTA Chelator GMP Grade Radiometal market is projected to grow from USD 268 million in 2026 to USD 512 million by 2034, exhibiting a CA...
www.24chemicalresearch.com
August 17, 2026 at 12:07 PM
He started by talking about 89Zr complexes for diagnostics that are currently explored in clinical trials. (2/4) pubs.rsc.org/en/content/a...
An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes
89Zr-based imaging agents hold great promise as novel radio-tracers in nuclear medicine. However, insufficient stability of currently used radiometal complexes in vivo is a safety concern for clinical...
pubs.rsc.org
October 24, 2025 at 10:59 AM
Fête de la musique au travail, on fait découvrir de nouveaux horizons au collègue 😈😁
June 20, 2025 at 6:41 AM
Radiopharma fans take note: Oz's Telix now trading on NASDAQ. Telix recently bolstered U.S. footprint by buying RLS (USA) unit of RLS Group Ltd. for up to $250M. Telix aims to build a radiometal distribution network leveraging its 30+ radiopharmacies across the U.S. h/t @biobonanos.bsky.social
November 14, 2024 at 1:11 AM
This review in Chemical & Biomedical Imaging examines chelators, radiometals, and peptide modifications that influence stability, targeting, and imaging performance.

Read the full article: doi.org/10.1021/cbmi...
#ChemicalBiomedicalImaging #PeptidePET #Radiopharmaceuticals
Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine
Abstract. The development of peptide-based, radiometal-labeled PET imaging agents has seen an increase in attention due to the favorable properties the pep
doi.org
September 18, 2026 at 1:23 AM
“A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements” by Rachel Codd et al. (doi.org/10.1039/D4SC...)
A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements
A covalent adduct of DFOB and DOTA separated by a l-lysine residue (DFOB-l-Lys-N6-DOTA) exhibited remarkable regioselective metal binding, with {1H}-13C NMR spectral shifts supporting Zr(iv) coordinating to the DFOB unit, and Lu(iii) coordinating to the DOTA unit. This first-in-class, dual-chelator theranost
doi.org
May 23, 2025 at 8:00 AM
"A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements"
doi.org/10.1039/D4SC...

Registration for the symposium is currently open and we are accepting poster abstracts until 8 September 2025: rsc.li/chemscisymp2025
September 5, 2025 at 7:00 AM
Product Description
Adarulatide tetraxetan (CAS No. 1246013-02-4), also known as Copper adarulatidum tetraxetanum, is a synthetic peptide conjugate that functions as a chelator-based diagnostic imaging agent. #CGMP
arizona-mall.com/product/adar...
Adarulatide Tetraxetan (CAS No. 1246013-02-4) – Copper-Labeled Diagnostic Imaging Agent
Adarulatide tetraxetan is a chelator-conjugated peptide compound used for radiolabeling and diagnostic imaging. It enables site-specific radiometal binding, particularly with copper isotopes, to visualize tumor targets in molecular imaging research.
arizona-mall.com
October 4, 2025 at 8:29 AM
DOTA-NOC (DOTA-Nal³-Octreotide) – High-Affinity Somatostatin Receptor Ligand – Purity 99.22% – GMP Manufacturer

DOTA-NOC is a GMP-grade, high-purity ligand selective for somatostatin receptor subtypes 2, 3, and 5. Designed for radiometal labeling and radiopeptide imaging, it supports both…
DOTA-NOC (DOTA-Nal³-Octreotide) – High-Affinity Somatostatin Receptor Ligand – Purity 99.22% – GMP Manufacturer
DOTA-NOC is a GMP-grade, high-purity ligand selective for somatostatin receptor subtypes 2, 3, and 5. Designed for radiometal labeling and radiopeptide imaging, it supports both wholesale and retail with research-use-only compliance.(For wholesale prices, other specifications and uses, please consult our staff)
arizona-mall.com
August 15, 2025 at 8:28 AM
RRIDs were included in this in Advanced Science paper. Thanks for making your methods matter! #methodsmatter #STMpublishing #RRID
Ultra-Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal-Labeling Platform for Cancer Radioembolization
Read the full paper: Ultra-Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal-Labeling Platform for Cancer Radioembolization
doi.org
June 26, 2026 at 7:00 AM
#podcast #bd #radiometal

le lien permanent vers mon émission de Novembre

www.podcastics.com/podcast/epis...
Du Metal Dans Les Bulles - Novembre 2024
Troisième épisode de la deuxième saison pour l'émission qui lie le metal, les Comics et la BD !
www.podcastics.com
November 20, 2024 at 8:45 AM
#Cicanews
📅 Vindeiro luns 17 de febreiro ás 16h
👩‍🔬Encontro dixital con Dr. Caterina Ramogida
"Moving beyond DOTA: Tailored chelating ligands to complex exotic radiometal ions for theranostic radiopharmaceuticals"

👉Máis detalles na web: cica.udc.gal/event/confer...
Conferencia Red MetalBio - Caterina Ramogida | CICA
El CICA es el Centro Interdisciplinar de Química e Bioloxía. Se encarga del desarrollo de proyectos de investigación.
cica.udc.gal
February 10, 2025 at 12:28 PM
#CICAnews
📅 Next Monday, February 17th at 16h
👩‍🔬Online meeting with Dr. Caterina Ramogida
"Moving beyond DOTA: Tailored chelating ligands to complex exotic radiometal ions for theranostic radiopharmaceuticals"

👉 Further details at our site: cica.udc.gal/event/confer...
@udc.gal #researching
February 10, 2025 at 12:28 PM
Chelator-Free Radiometal Labeling Inside Engineered Affibodies https://www.biorxiv.org/content/10.64898/2026.01.28.702152v1
January 29, 2026 at 4:46 AM
Chelator-Free Radiometal Labeling Inside Engineered Affibodies https://www.biorxiv.org/content/10.64898/2026.01.28.702152v1
January 29, 2026 at 4:46 AM
¤ Radios Libres ¤ Best of 2024 (1ère partie): Comme tous les ans l'émission Noise Pollution s'associe avec Metal Brigade de radiometal pour un best of en 2 émissions. Cette année ce sera les 3 et 10 janviers à 20h sur radio Canut et plus… ¤ Podcast ¤ #Metal #RadioCanut #NoisePollution #BestOf2024
Best of 2024 (1ère partie)
Comme tous les ans l'émission Noise Pollution s'associe avec Metal Brigade de radiometal pour un best of en 2 émissions. Cette année ce sera les 3 et 10 janviers à 20h sur radio Canut et plus tard sur radio Metal. Le blog de Noise pollution :…
dlvr.it
January 1, 2025 at 2:50 PM
Our IONT platform solves this by directly integrating the radiometal into the nanoparticle core
With one 10 minute microwave synthesis, we achieve:
✔️ High radiolabeling yields
✔️ Excellent serum stability
✔️ Identical nanoparticle properties regardless of the isotope
A plug and play system.
4/7
February 20, 2026 at 10:16 AM
In nuclear medicine, each radiometal usually needs its own chelator, each with its own limitations. There’s no single chelator that works for all.
The situation is like this
3/7
February 20, 2026 at 10:16 AM
We show our vision for radiopharmaceuticals. Chelators have provided many successes but falls short in key aspects: achieving good yields with low radiometal quantities and/or metal impurities, enabling fast bioconjugation, and offering similar chemistry across various radiometals. (2/6)
July 16, 2025 at 6:48 AM
Ultra‐Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal‐Labeling Platform for Cancer Radioembolization
Ultra‐Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal‐Labeling Platform for Cancer Radioembolization
Conjugated poly(imide dioxime)-based microspheres establish a radiometal coordination-driven conformational interlocked network with ultra-high radiostability. This platform enables low-temperature, multi-radionuclide labeling for SPECT/PET/MRI imaging and radionuclide therapy. Mechanistic insights from EXAFS and DFT reveal enhanced stability, while in vivo studies demonstrate effective tumor targeting, supporting clinical translation for liver cancer theranostics. ABSTRACT Transcatheter arterial embolization (TARE) has emerged as a highly effective locoregional treatment for advanced liver cancer, which represents a significant advancement in clinical practice. Nonetheless, the utilization of traditional radioactive microspheres in TARE is hindered by various material and technical challenges that necessitate resolution. Herein, we present, for the first time, well-designed and synthesized conjugated poly(imide dioxime) ligand-based microspheres (PID-Ms) with a remarkable radiometal coordinate covalent conformational interlocked network. PID-Ms can be radiolabeled with various radionuclides, including 177 Lu, 90 Y, 188 Re, 68 Ga, and 99m Tc, can be achieved at low temperatures (40°C), and for diagnostic imaging and radiotherapy applications. The combined strategy of extended x-ray absorption fine structure spectroscopy (EXAFS), DFT calculations, and in vitro and in vivo radiostability experiments collectively confirmed that radiometal-PID complexes exhibit ultra-high radiostability. 177 Lu-PID-Ms were employed to accurately predict normal organ shunts and radiotherapy in rat and rabbit VX2 orthotopic live tumor models, demonstrating their ultra-radiostability and remarkable anti-tumor efficacy. Furthermore, Radiometals-PID-Ms have an adjustable shelf life, enabling on-demand radiolabeling for drug preparation, achieving rapid ‘on-demand’ capability. This innovative approach has the potential to inspire the synthesis of numerous coordination polymeric materials for various applications in PET/SPECT-mediated radiopharmaceutical therapy, alpha-nucleophile-targeted radiotherapy, and MRI contrast agents.
advanced.onlinelibrary.wiley.com
June 24, 2026 at 4:35 PM